Bayesian Quantitative Disease–Drug–Trial Models for Parkinson’s Disease to Guide Early Drug Development
Journal Title: The AAPS Journal - Year 2011, Vol 13, Issue 4
Abstract
The problem we have faced in drug development is in its efficiency. Almost a half of registration trials are reported to fail mainly because pharmaceutical companies employ one-size-fits-all development strategies. Our own experience at the regulatory agency suggests that failure to utilize prior experience or knowledge from previous trials also accounts for trial failure. Prior knowledge refers to both drug-specific and nonspecific information such as placebo effect and the disease course. The information generated across drug development can be systematically compiled to guide future drug development. Quantitative disease–drug–trial models are mathematical representations of the time course of biomarker and clinical outcomes, placebo effects, a drug’s pharmacologic effects, and trial execution characteristics for both the desired and undesired responses. Applying disease–drug–trial model paradigms to design a future trial has been proposed to overcome current problems in drug development. Parkinson’s disease is a progressive neurodegenerative disorder characterized by bradykinesia, rigidity, tremor, and postural instability. A symptomatic effect of drug treatments as well as natural rate of disease progression determines the rate of disease deterioration. Currently, there is no approved drug which claims disease modification. Regulatory agency has been asked to comment on the trial design and statistical analysis methodology. In this work, we aim to show how disease–drug–trial model paradigm can help in drug development and how prior knowledge from previous studies can be incorporated into a current trial using Parkinson’s disease model as an example. We took full Bayesian methodology which can allow one to translate prior information into probability distribution.
Authors and Affiliations
Joo Yeon Lee, Jogarao V. S. Gobburu
Keywords
Related Articles
- EP ID EP681338
- DOI 10.1208/s12248-011-9293-6
- Views 84
- Downloads 0
Successes Achieved and Challenges Ahead in Translating Biomarkers into Clinical Applications
Biomarkers are important tools for identifying and stratifying diseases, predicting their progression and determining the effectiveness, safety, and doses of therapeutic interventions. This is important for common chroni...
Vectors for airway gene delivery
Delivery of genes to the airway epithelium for therapeutic purposes seemed easy at first, because the epithelial cells interface with the environment and are therefore accessible. However, problems encountered were more...
Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using In Vitro and Preclinical In Vivo Data
Accurate predictions of human pharmacokinetic and pharmacodynamic (PK/PD) profiles are critical in early drug development, as safe, efficacious, and “developable” dosing regimens of promising compounds ha...
Rheological Evaluation of Silicon/Carbopol Hydrophilic Gel Systems as a Vehicle for Delivery of Water Insoluble Drugs
The present study analyzed the thickening properties of Carbopol 974 and 971 in a 50:50 mixture of water/Silsense™ A-21, a new cationic silicon miscible in any proportion with water. Samples were prepared by simp...
A Novel MDR1 GT1292-3TG (Cys431Leu) Genetic Variation and Its Effect on P-glycoprotein Biologic Functions
P-glycoprotein (P-gp) is a membrane-bound transporter protein that is encoded by the human multidrug resistance gene MDR1 (ABCB1). P-gp recognizes a wide range of xenobiotics, is pivotal in mediating cancer drug resistan...